Clinical trials: sponsored by Henan Cancer Hospital
Refractory, Relapsed
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for…
- Conditions
- Refractory, Relapsed, B Cell Lymphoma, B Cell Leukemia
- Trial name
- NCT03881774
- Testing
- CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer Extensive Stage
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Patients with extensive disease SCLC after failure of first-line treatment were enrolled with SHR-1210 and epirubicin for 3 cycles to evaluate initial efficacy
- Trial name
- NCT03755115
- Testing
- Epirubicin plus SHR1210
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Relapsed/Refractory Myeloma
BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
Evaluation of the safety and efficacy of BCMA nanobody CAR-T cells in relapsed/refractory myeloma
- Trial name
- NCT03664661
- Testing
- BCMA nanobody CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Henan Cancer Hospital
Relapsed Non Hodgkin Lymphoma
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
Evaluation of the safety and efficacy of CAR19 T cells carrying cytoplasmic activated PD1 in patients with refractory relapsed B-cell lymphoma
- Trial name
- NCT03540303
- Testing
- CAR19 T cells carrying cytoplasmic activated PD-1
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Henan Cancer Hospital
Adenocarcinoma of the Stomach / Gastroesophageal
The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal
Evaluate survival benefit of surgical treatment after FLOT regimen conversion therapy of Her-2 Negative and single site metastasis adenocarcinoma of the stomach / gastroesophageal compared with chemotherapy, use relevant…
- Trial name
- NCT03451942
- Testing
- FLOT regimen chemotherapy, D2 gastric and imaging metastases resection
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Henan Cancer Hospital
Head and Neck Squamous Cell Carcinoma
A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to confirm the safety and efficacy of Apatinib in Combination With Radiotherapy / Chemotherapy for Second-line and Above Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT03424291
- Testing
- Apatinib plus chemoradiation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer
An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer
The real-world observational study was designed to explore lymph metastases and prognoses of the Chinese patients with thoracic T1-T3 esophageal cancer
- Trial name
- NCT03415815
- Testing
- Surgeries
- Where
- 10 sites in China
- Volunteers
- 3,673 people
- Sponsor
- Henan Cancer Hospital
Multiple Myeloma
Study of BCMA CAR-T in Multiple Myeloma
The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy.
- Trial name
- NCT03322735
- Testing
- Fludarabine, Cyclophosphamide, BCMA CAR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Henan Cancer Hospital
B-cell Acute Lymphoblastic Leukemia
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
This is a study for patients who have been previously treated for B-ALL. The purpose of this study is to determine the safety and feasibility of CART-19 cells to the patients with relapsed and refractory CD19+ B-ALL.
- Trial name
- NCT02924753
- Testing
- Cyclophosphamide, Fludarabine, CART-19 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Malignant Melanoma
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.
- Trial name
- NCT03383237
- Testing
- Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Lung Adenocarcinoma
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
The purpose of this study is to confirm the safety and efficacy of Apatinib plus Pemetrexed as the Maintenance Therapy in Advanced Lung Adenocarcinoma.
- Trial name
- NCT03376737
- Testing
- Apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Henan Cancer Hospital
B-cell Acute Lymphocytic Leukemia
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
The purpose of this study is to infusion CD19 CAR-T cells to the patients with relapsed and refractory CD19+ B cell leukemia, to assess the safety and feasibility of this strategy.
- Trial name
- NCT03263208
- Testing
- Cyclophosphamide, Fludarabine, CD19 CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Advanced Esophagus Cancer
Apatinib Treatment for Advanced Esophagus Cancer
Subject ever received a standard chemotherapy solution progression or recurrence or can't tolerate chemotherapy with advanced esophageal squamous carcinoma.
- Trial name
- NCT03170310
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Osteosarcoma, Advanced
Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.
Apatinib second line treatment for Advanced osteosarcoma and soft tissue sarcomas ,openting ,single center, one-armed clinical study.
- Trial name
- NCT03163381
- Testing
- Apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
B Cell Lymphoma
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
This is a clinical study to observe the safety and feasibility of chimeric antigen receptor 19 (CART-19) cells in relapsed and refractory patients with CD19+ B cell lymphoma.
- Trial name
- NCT03101709
- Testing
- Cyclophosphamide, Fludarabine, CART-19
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital